- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (335)
7 result(s) found for: HEPA.
Displaying page 1 of 1.
| EudraCT Number: 2014-000537-24 | Sponsor Protocol Number: IIS-HEPA-TEST | Start Date*: 2014-07-16 |
| Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
| Full Title: Pilot clinical trial phase I / IIa to determine condition, low dose and effectiveness of liver function tests (Hepatotest) | ||
| Medical condition: Hepatic Function. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-002629-23 | Sponsor Protocol Number: 100449 | Start Date*: 2015-05-22 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: Immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-Hepatitis B vaccine (10 µg) in newborns of Hepa-titis B envelope antigen positive (HBeAg+) and Hepatitis B surface antigen... | ||
| Medical condition: Hepatitis B vaccination in healthy newborns of HBeAg+ and HBsAg+ mothers | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-003817-32 | Sponsor Protocol Number: LOLA-Merz:WMDHP39937 | Start Date*: 2013-01-08 | |||||||||||
| Sponsor Name:Imperial College London | |||||||||||||
| Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate | |||||||||||||
| Medical condition: Hepatic Encephalopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002924-11 | Sponsor Protocol Number: LOLAbiome | Start Date*: 2023-01-09 | ||||||||||||||||
| Sponsor Name:CBmed GmbH | ||||||||||||||||||
| Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis | ||||||||||||||||||
| Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-016055-22 | Sponsor Protocol Number: Reuma hepA | Start Date*: 2009-11-27 | |||||||||||
| Sponsor Name:HY, HUS | |||||||||||||
| Full Title: Immuunipuutteisten matkailijoiden A-hepatiittisuojaus | |||||||||||||
| Medical condition: Terveet vapaaehtoiset ja vapaaehtoiset potilaat, joilla on diagnosoitu nivelreuma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001703-41 | Sponsor Protocol Number: WTX101-201 | Start Date*: 2014-08-18 | |||||||||||
| Sponsor Name:Alexion Pharmaceuticals, INC. | |||||||||||||
| Full Title: A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Pha... | |||||||||||||
| Medical condition: Wilson Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) PL (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006021-14 | Sponsor Protocol Number: BAY43-9006/12917 | Start Date*: 2009-07-01 | ||||||||||||||||
| Sponsor Name:Bayer AG | ||||||||||||||||||
| Full Title: A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | ||||||||||||||||||
| Medical condition: To evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotibib 150 mg once a day in subjects with unresectable advanced or metastatic Child-Pugh A HCC. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) AT (Completed) GR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.